Ad hoc: Evotec and Bristol Myers Squibb extend and expand strategic partnership

Evotec SE  announces today that the Company has extended and expanded its partnership with Bristol Myers Squibb (NYSE:BMY) in targeted protein degradation, originally signed in 2018.

Read More